Is PT-141 approved for general use?

The approval covers one population and one indication. Material sold as PT-141 outside a pharmacy is not the approved product and has not been through the same manufacturing controls.

How much research exists on bremelanotide?

One hundred and nine PubMed records, of which eighty are tagged to human subjects and fifteen are typed as clinical trials. That is a real but small literature, and it sits almost entirely within the approved indication.

Bremelanotide: what the evidence actually shows

Bremelanotide is a melanocortin receptor agonist approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.

Also known as PT-141, Vyleesi, PT141.

Evidence and regulatory status

Approved for human use, with published phase 3 data.

Approved by the FDA as Vyleesi in June 2019 for hypoactive sexual desire disorder in premenopausal women.

Half-life

A half-life figure for Bremelanotide has not been verified against a primary source for this page, so none is stated. The sources below are where a figure would come from.

What published trials used

The registration trials administered 1.75mg by subcutaneous autoinjector, taken as needed before anticipated sexual activity.

Reported for reference only. What a trial administered under supervision is not a recommendation, and Gireta does not make one.

How much research exists

PubMed records: 109
Tagged human: 80
Clinical trials: 15

A PubMed search for Bremelanotide returns 109 records, of which 80 are tagged as human research and 15 are typed as a clinical trial.

Counted on 2026-09-04. Counts drift, so the exact query is linked rather than described, and you can re-run it.

Common questions

Is PT-141 the same as Vyleesi?: Yes. The FDA approved bremelanotide as Vyleesi in June 2019, for hypoactive sexual desire disorder in premenopausal women. It is the same molecule sold in research channels as PT-141.
Is PT-141 approved for general use?: The approval covers one population and one indication. Material sold as PT-141 outside a pharmacy is not the approved product and has not been through the same manufacturing controls.
How much research exists on bremelanotide?: One hundred and nine PubMed records, of which eighty are tagged to human subjects and fifteen are typed as clinical trials. That is a real but small literature, and it sits almost entirely within the approved indication.

Sources

Vyleesi label · DailyMed, US National Library of Medicine, 2025
Bremelanotide approval review · Annals of Pharmacotherapy, via PubMed, 2020

Related compounds

Melanocortin receptor agonists

Act on melanocortin receptors, which is why pigmentation and nausea recur across the class.

Melanotan II Melanotan II is a synthetic analogue of alpha-melanocyte-stimulating hormone that increases melanin production in the skin.

Planning a schedule?

Gireta turns a compound and a cadence into a twelve-week timeline with the reconstitution maths worked out and a monthly cost.

Plan a Bremelanotide schedule

Last reviewed 2026-09-04.